Stepping forward: A study protocol for developing and validating a Malaysian diabetic foot self-care practice assessment instrument Authors: Divya Nair Narayanan, Samsiah Awang, Yee Gary Ang, Yee Gary Ang, Yee Gary Ang, Yee Gary Ang Published: 2025 ABSTRACT IntroductionDiabetic foot ulcers impose significant financial burdens and diminished quality of life. Effective management relies on patients’ self-care, yet often overlooked by patients as neuropathic feet are painless. In Malaysia, primary care facilities focus on prevention by promoting proper foot self-care. However, the lack of a standardised assessment tool hampers nationwide evaluation. This paper outlines the methodology for developing and validating an instrument tailored to the Malaysian context to assess diabetic foot self-care practices.MethodsA structured methodological process will be employed to guide the instrument’s development and subsequent validation. The instrument aims to encompass comprehensible questions with a simple scoring and interpretation mechanism to foster its daily use. The study will consist of two phases. Phase 1 focuses on the development of the Malaysian instrument. This phase encompasses a literature review, item development tailored to the Malaysian context, content validity through expert panel evaluations, translations, pre-tests and a follow-up stakeholder engagement to ensure the instrument meets their requirements. Incorporating perspectives from experts and comprehensibility by local patients ensures the instrument’s relevance to the local context. Phase 2 involves instrument validation through a cross-sectional study. This phase entails a pilot test and field test of the instrument among diabetic patients for validation. Cut-off ranges and their interpretations will also be established in this phase. The study sites encompass a mix of urban and rural public health clinics across Peninsular as well as East Malaysia.DiscussionBy developing a standard validated instrument to assess diabetic foot self-care practices, services provision gaps can be identified, and targeted interventions to improve these gaps in practices can be implemented. Individually tailored diabetes foot care education is crucial in preventing foot ulcers. This instrument can also facilitate the monitoring of improvements in patients’ foot self-care practices longitudinally. Introduction Diabetes mellitus and its implications Diabetes mellitus (DM), a silent epidemic, is a syndrome of chronic hyperglycaemia due to relative insulin deficiency, resistance or both [1]. Chronic hyperglycaemia can damage various organ systems leading to disabling and life-threatening health complications, most prominent of which are microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular complications leading to an increased risk of cardiovascular diseases [2,3]. According to the Malaysian National Health Mortality and Morbidity Survey (NHMS) 2019 report, the prevalence of DM among Malaysians has increased from 13.4% in 2015 to 18.3% in 2019 [4]. The NHMS 2023 reported that 1 in 6 adult Malaysians have diabetes, of which among the adults who are aware they have diabetes, 56% do not have good blood glucose control [5]. Diabetic foot ulcer is defined as infection, ulceration, or destruction of tissues of the foot associated with peripheral neuropathy and/or peripheral arterial disease (PAD) of people with DM [6]. About 19–34% of diabetic patients develop foot ulcers at some stage in their lives [7]. Diabetic foot ulcer is a serious complication that has led to more than 80% of non-traumatic limb amputations [8] with an approximately 50% 5-year mortality [9,10]. Diabetic foot ulcers incurred an estimated cost of about RM6,000 per patient per year [11,12] in Malaysia. Besides the cost of foot complications, there are also the negative impacts relating to a loss of productivity, individual patient and family costs and loss of health-related quality of life. It poses an extensive burden to the affected individuals and the healthcare system causing socio-economic problems, consequently increasing healthcare expenditure [13,14]. Self-care behaviours and diabetic foot management in Malaysia Self-care behaviours are actions taken by an individual to control health problems [15], which is a basic requirement for the effectiveness of integrative treatment in chronic diseases, such as DM. Because a major part of diabetic care is undertaken by the patient, minimisation if not complete prevention of foot complications heavily depends on their self-care skills [16–19]. A previous study showed that patients with diabetes often neglect foot self-care practices due to painless neuropathic feet, which may increase the risk of diabetic foot ulcers, and concluded that these self-practices appear to be under-utilised as a primary complication prevention measure [20]. Foot self-care practices such as patient education appear to be more aggressively delivered once patients have already developed foot ulcers [20]. Although becoming accustomed to daily foot self-care such as daily foot examination can be challenging for patients with DM, these behaviours could effectively prevent foot problems by 49–85% [21], making timely foot self-management training a priority in diabetic foot ulcer prevention programs [22,23]. Prior to instructing a patient on proper foot self-care techniques, it is essential healthcare providers first understand the patient’s current practices [24]. This process can be streamlined and expedited, particularly for healthcare providers managing heavy workloads, with the aid of an instrument to assess self-care practices in DM patients. In Malaysia, DM is managed by a multi-disciplinary team, which also includes diabetic foot care. Prevention of diabetic foot ulcers is a service primarily carried out at primary care facilities. This service involves empowering patients, ensuring regular reinforcement, promoting adherence to proper foot care practices, and early recognition of ulcers. Presently, although foot self-care practices of diabetic patients are assessed; nevertheless, the assessment may be non-standardised nationwide, as there is a lack of an instrument for objective assessment. This hinders the ability to effectively compare the quality of foot self-care services offered among facilities nationwide. Existing instruments on diabetic foot self-care and rationale of study A preliminary review was conducted to identify existing instruments and questionnaires used to assess diabetic foot self-care practices. This initial exploration aimed to serve as a guide and foundation for informing the development of a Malaysian instrument, to be made contextually relevant and tailored to Malaysian needs. Table 1 presents the preliminary overview findings of the various domains explored (but not limited to) in existing instruments and KAP studies. Table 2 provides a summary of selected existing instruments (but not limited to) identified from the preliminary overview, which informed the conceptual and structural considerations for the Malaysian instrument. 10.1371/journal.pone.0337754.t001Table 1Preliminary overview – List of various domains identified from existing instruments and KAP studies [24–40].DOMAINS IDENTIFIEDInspection of footShoe to fit (feet measurement)Washing of feetBreaking into shoesDrying of feet/ in between toesTreatment of foot problemsTesting water temperatureUse of moisturisers/ talcumsNail careUse of socksChecking inside shoesWalking barefootSmoking affecting the health of feetKnowing when to seek treatmentImportance of anti-diabetic treatmentSoaking of feetExposure of feet to heatTypes of footwearAddition of irritants to waterAssigning designated time for foot careImportance of foot careAddressing wet feet Preliminary overview – List of various domains identified from existing instruments and KAP studies [24–40]. 10.1371/journal.pone.0337754.t002Table 2Preliminary overview – Summary of existing instruments.NO.INSTRUMENT NAMEDIMENSIONSITEMSSCORINGCOUNTRY OF ORIGIN1Diabetic foot self-care questionnaire of the University of Malaga, Spain (DFSQ-UMA) [36] Foot careShoe carePersonal care 16LikertSpain2Nottingham Assessment of Functional Footcare (NAFF) (revised) [32] Foot conditionFoot hygieneShoesFoot moisturiserNail carePrevention of foot injuriesTreatment of foot injuriesUse of heating items 29Behavioral frequency scoringUnited Kingdom3Diabetes foot self-care behaviour scale (DFSBS) [37] Foot inspectionWashingDryingToe inspectionLotion applicationShoe use 7Combination of Likert + Yes/NoTaiwan4Knowledge and practices regarding foot care in diabetic patients in Jinnah Hospital, Lahore [38] Compliance to medicationsFoot careShoesIdentification of warning signs 15Yes/NoPakistan5Foot Care Confidence Scale/ Foot-Care Behaviour instrument(FCCS-FCB) [39] Self-efficacyPreventive self-care behavioursRisky self-care behaviours 29Combination of Likert + Yes/NoMexico6Modified Diabetic Foot Care Knowledge and Modified Diabetic Foot Care Behaviours (MDFCK-MDFCB) [40] General DM managementFoot conditionFoot hygieneShoesFoot moisturiserNail carePrevention of foot injuriesTreatment of foot injuries 34True/False + LikertIndonesia Preliminary overview – Summary of existing instruments. Foot care Foot care Shoe care Shoe care Personal care Personal care Foot condition Foot condition Foot hygiene Foot hygiene Shoes Shoes Foot moisturiser Foot moisturiser Nail care Nail care Prevention of foot injuries Prevention of foot injuries Treatment of foot injuries Treatment of foot injuries Use of heating items Use of heating items Foot inspection Foot inspection Washing Washing Drying Drying Toe inspection Toe inspection Lotion application Lotion application Shoe use Shoe use Compliance to medications Compliance to medications Foot care Foot care Shoes Shoes Identification of warning signs Identification of warning signs Self-efficacy Self-efficacy Preventive self-care behaviours Preventive self-care behaviours Risky self-care behaviours Risky self-care behaviours General DM management General DM management Foot condition Foot condition Foot hygiene Foot hygiene Shoes Shoes Foot moisturiser Foot moisturiser Nail care Nail care Prevention of foot injuries Prevention of foot injuries Treatment of foot injuries Treatment of foot injuries Existing literature has evidenced various instruments designed to assess self-care in DM patients. These instruments may either assess overall self-care, encompassing multiple components such as physical activity, medication adherence, follow-up compliance, smoking habits, diet control, foot care, and blood glucose monitoring, or focus solely on specific components [24–40]. Nevertheless, a few limitations were identified. Some of these instruments contain many items or use disaggregated component-based scoring mechanisms [24–30,33–35,39]. This may reduce both patient responses and uptake by healthcare providers due to their reduced user-friendliness and practicality for daily use. Healthcare providers often face difficulties deciding whether to assess the patient based on the total score or component subscales. Existing instruments differ, with certain items reflecting culture-specific differences in population habits. For example, practices like daily use of socks or heating pads for the feet during cold seasons may be more relevant in Western countries [24,25,27,30–33,35,36,38,39,41–44] but less relevant in Malaysia. Occupational therapists in Malaysia encountered challenges in adopting Vileikyte’s instrument [25]. These include the irrelevance of certain questions, despite translation efforts, and the impracticality of domain-based scoring for daily use, which resulted in reduced uptake. Given these challenges and to better align with Malaysian stakeholder needs, it was deemed more advantageous to conduct a literature review to explore relevant evidence and subsequently develop a Malaysian instrument. This approach ensures that the Malaysian instrument is comparable to existing instruments while being tailored to the specific requirements of the local context. A standardised and validated instrument for assessing diabetic foot self-care practices, when embraced by healthcare providers, facilitates the identification of service gaps and the implementation of individually tailored interventions to improve foot care. It can be used to track improvements in patients’ foot self-care practices over time and aid in developing a formal module for diabetes-related foot care education, addressing a resource gap for occupational therapists. This instrument aims to be user-friendly for daily practice while demonstrating adequate validity and reliability. Therefore, this paper aims to outline the methodology for developing and validating a diabetic foot self-care practice assessment instrument to be used among diabetic patients referred for foot self-care services in Malaysian healthcare facilities. Engaging relevant stakeholders Recognising the multifaceted nature of diabetic foot care, although the Occupational Therapy (OT) profession serves as the primary stakeholder that requested the instrument, other stakeholders such as the Family Health Development Division, Family Medicine Specialists, the Non-Communicable Disease Sector under the Disease Control Division and diabetic educators were also engaged. These stakeholders will be engaged periodically to ensure the instrument aligns with their needs. While diabetic foot care is multi-disciplinary, the instrument is intended for adoption by the OT profession for nationwide implementation in primary care clinics. Methodology Study type and design This study will be conducted in two phases. Phase 1 involves the development of the diabetic foot self-care practice assessment instrument, and Phase 2 involves the validation of the instrument through a cross-sectional study design. Phase 1: Development of the Malaysian instrument Phase 1 involves a literature review, item development tailored to better suit the Malaysian context, content validity through expert panel evaluations, translations, pre-tests and a follow-up stakeholder engagement. Fig 1 depicts the flow process. Phase 1 workflow. a) Literature review. A literature review will screen articles on instruments assessing diabetic foot self-care as well as knowledge, attitude and practice (KAP) questionnaires. Including KAP articles will help explore the ‘practice’ component, providing insights into the diverse but potentially relevant items and methods of inquiry. These insights will inform the development of the Malaysian instrument by drawing on the strengths and addressing the limitations of instruments used in other countries, while ensuring cultural and contextual relevance to the Malaysian setting. The review will also explore available scoring systems and interpretations (where available) to guide the design of an appropriate scoring framework for the Malaysian instrument. All the information extracted will be systematically tabulated to inform the development process (refer to Annex 1 in S1 File). This literature review will involve a search through relevant search engines such as PubMed, Scopus, Embase and CINAHL for articles and reports using the following Medical Subject Heading terms (MESH terms): “Diabetic foot” OR “diabetic feet” OR “diabetic foot ulcer” OR “diabetic foot problem” AND “self-care practice” OR “self-care behaviours” OR “self-efficacy” OR “self-management” AND “questionnaire” OR “survey” OR “instrument” OR “tool”. The articles will be limited to those reported in English and Bahasa Malaysia, with no time limits. b) Adaptations and modifications. Insights from the literature review will guide the development of the proposed Malaysian instrument. The proposed instrument will be developed following the parsimonious principle [45] and utilise a Likert scale for scoring to facilitate ease of interpretation and response consistency. The Likert scale and number of items incorporated will prioritise practicality for daily use as well as ensuring usability for both healthcare professionals and patients. The design will emphasise simplicity, ease of use, and clarity, to encourage uptake by healthcare providers, accommodating their time constraints and workload. A straightforward, time-efficient instrument is also likely to improve patient cooperation. A brief section for collecting the sociodemographic profile of diabetic patients will also be developed. The proposed instrument will then be assessed by the expert panel for content validity. c) Content validity of the proposed instrument. The expert panel consisting of 5–6 experts [46] will be identified based on their area of expertise, years in service, and depending on the availability of the individual. This panel will consist of, but not limited to: Policymakers from the Allied Health Sciences Division Policymakers from the Allied Health Sciences Division Program planners from the Occupational Therapy Service Program planners from the Occupational Therapy Service Occupational therapists managing diabetic foot care at the facility level Occupational therapists managing diabetic foot care at the facility level Endocrinologist or Family Medicine Specialist Endocrinologist or Family Medicine Specialist Diabetic educators managing diabetic foot care at the facility level Diabetic educators managing diabetic foot care at the facility level Other health professionals managing diabetes at the facility level Other health professionals managing diabetes at the facility level Each content expert will receive an evaluation kit comprising a cover letter, an informed consent form, the instrument consisting of the items and scoring, and the evaluation criteria form. The cover letter will outline the study’s purpose, rationale for selecting the content expert, a description of the instrument, and the content evaluation procedure. The evaluation criteria form will utilise a 4-point rating scale [46] to establish the content validity. Experts will evaluate the relevance, clarity of items, presentation, adequacy, and attainment of purpose of the instrument (refer to Annex 2 in S1 File). Feedback on the scoring mechanism will also be gathered to assess its user-friendliness in the daily Malaysian context. The experts will be requested to provide recommendations for each item they have scored low (1 or 2). They will be given two weeks to complete the evaluation and return it to the research team. The content validity of the instrument will be established through the Content Validity Index (CVI), namely: i) Item-level CVI (I-CVI) and; ii) Scale-level CVI (S-CVI) [46]. The draft instrument and the scoring mechanism will be revised iteratively using the Delphi technique until consensus is reached [47], resulting in Version 1 of the instrument. The Delphi method is a structured process for collecting expert opinions through multiple survey rounds. After each round, feedback is provided, allowing participants to refine their responses until consensus is reached [47]. This process ensures that the instrument captures key aspects of diabetic foot self-care, considering local nuances and socio-cultural factors. d) Forward-backward translations of the proposed instrument. Version 1 of the instrument will be developed in English, then translated into Bahasa Malaysia and back-translated into English to ensure the original meaning, syntax, and wording are retained. Professionals proficient in both languages and not affiliated with the study will conduct these translations. Cross-comparisons between the translator and the research team will resolve any discrepancies. e) Pre-test: Face validity and cognitive debriefing. The dual-language version of the instrument will be pre-tested by occupational therapists among a group of 10 diabetic patients, who are from the intended respondent population, through purposive sampling [48]. These patients will be recruited based on age, ethnicity, gender, and education level [49]. The face validity process ensures the items are arranged meaningfully with a clear structure of the opening questions. Quantified using the Face Validity Index (FVI), this process will be assessed through a standardised form. A “yes” or “no” option will be used to evaluate the overall features, including clarity, conciseness, ease of understanding, and typographical accuracy (refer to Annex 3 in S1 File). Cognitive debriefing will be done to capture the clarity, language, and comprehensibility of the proposed items and scoring options. The instrument will be self-administered. A consent form will be used to obtain consent from patients prior to the pre-test data collection. The patients selected for the pre-test will differ from those participating in the pilot and field tests. The responses from the pre-test will be used to further refine the instrument as an iterative process until the instrument is deemed satisfactory for the pilot test (Version 2 of the instrument). A follow-up stakeholder engagement will be conducted prior to the pilot test to ensure the instrument is aligned with their needs. Phase 2: Validation of the instrument Phase 2 is a validation study which will be conducted using a cross-sectional study design. This phase involves the reliability and validity analysis as well as establishing interpretation cut-off ranges for the instrument. Fig 2 depicts the flow process of the steps in Phase 2. Phase 2 workflow. a) Pilot test. For an instrument validation study, the pilot test assesses the preliminary feasibility of the instrument, and whether it collects all the relevant information intended to be collected [50], before deciding to conduct a full-scale field test. It can also help the research team familiarise themselves with the procedures in the instrument. Version 2 of the instrument will be used during the pilot test. The suggested sample size for conducting a pilot test is 30–35 [51]. Thus, 30–35 adult diabetic patients will be consecutively recruited from the targeted population. Occupational therapists will collect data using the self-administered instrument. A consent form will be used to obtain participant consent prior to data collection. Diabetic patients will complete the instrument on two separate occasions, once during their initial visit and again during a follow-up appointment. Although 1–2 weeks washout period is usually recommended [52], test-retest studies in literature use varying intervals [52]. In this study, the interval will be 1–6 weeks, aligning with the usual follow-up appointment schedule, allowing for a reasonable timeframe to assess stability in self-care behaviours while minimising patient burden. To minimise inconvenience and encourage participation, patients will be prompted to complete the instrument during their next follow-up appointment, with appointment reminders given via phone calls. Should the reliability from the first pilot test be unsatisfactory, amendments will be made, and the pilot test will be repeated until acceptable results are achieved. If the instrument’s reliability is satisfactory, the instrument (Version 3) will be used for the field test. b) Field test. The field test will involve a sufficiently large sample to assess the validity of Version 3 of the instrument. Patients will be recruited through consecutive sampling to maximise the number of respondents for validation of the instrument. During the field test, dimensionality will be assessed using exploratory factor analysis (EFA), and construct validity will be determined using confirmatory factor analysis (CFA). The minimum sample size required will be calculated using the rule-of-thumb for EFA, namely the 10:1 ratio [53]. Nevertheless, for the initial estimation, at least 100 observations are required for EFA [54]. To assess CFA, the minimum sample size will be calculated through power analysis using G*Power software. The DFSQ-UMA [36], a validated 16-item instrument used in Spain, will be utilised to calculate the estimated required sample size for CFA. With a medium effect size, an alpha of 0.05, a power of 0.8, and 16 predictors (based on the DFSQ-UMA), the estimated minimum sample size is 143. Accounting for a 20% non-response rate, the preliminary estimate suggests a minimum of 292 participants will be necessary for both EFA and CFA. Nevertheless, the final required sample size for the field test will depend on the number of items included in the proposed Malaysian instrument. Occupational therapists will collect data using the self-administered instrument. A consent form will be used to obtain participant consent prior to data collection. During the field test, the time taken by patients to complete the instrument will also be measured. Developing meaningful thresholds to aid the interpretation of patient-reported outcome measures (PROMs) has become standard practice due to the growing emphasis on patient-centered care [55]. Analysing field test data across age groups, major ethnicities, and urban/rural areas will allow for comparisons before setting standardised threshold scores for national interpretation. These thresholds aim to categorise diabetic patients into specific groups, such as poor, moderate, and good. This approach enhances precision and sensitivity, accurately reflecting the varying levels of self-care practices. These refined categories will support more informed decision-making for improving patients’ foot self-care practices. Study population and sampling The study population includes any diabetic patient referred for foot care in selected Ministry of Health primary care health clinics, as listed. The pilot and field tests will be conducted at occupational therapy departments of government primary care health clinics in selected states (based on regions, i.e., northern, southern, central, east-coast, Sabah, and Sarawak). Both urban and rural settings were factored in selecting study sites. Clinics were first purposively selected based on the availability of a permanent occupational therapist, followed by ensuring the clinics cater to an adequate patient population to meet the required sample size. In total, seven clinics were chosen as study sites. Five clinics (two urban, three rural) were selected as pilot test sites, while seven clinics (four urban, three rural), which included the pilot test sites, were selected as field test sites. These study sites were chosen for their high patient volume. Table 3 lists the proposed data collection sites. 10.1371/journal.pone.0337754.t003Table 3List of proposed data collection sites.NO.STATEREGIONCLINIC SETTINGAREATYPE OF TEST1.PerlisNorthernKampung Gial Health ClinicRuralPilot & field test2.SelangorCentralRasa Health ClinicRuralPilot & field test3.Kuala LumpurCentralKuala Lumpur Health ClinicUrbanField test4.TerengganuEast CoastManir Health ClinicUrbanPilot & field test5.JohorSouthernSungai Mati Health ClinicRuralPilot & field test6.SabahEast MalaysiaLuyang Health ClinicUrbanField test7.SarawakEast MalaysiaJalan Masjid Health ClinicUrbanPilot & field test List of proposed data collection sites. For the five clinics listed as both pilot and field test sites, different diabetic patients will be recruited for each test. Occupational therapists at these sites will maintain separate databases for pilot and field test patients, with patient identification numbers as identifiers to prevent patient overlap. Responses will be de-identified before submission to the research team for analysis. A training session on the instrument will be conducted prior to the pilot and field tests. This session will assist occupational therapists from the study sites in familiarising themselves with the instrument, ensuring a standardised understanding of the procedure, instrument, and technical specifications. To support application post-training, a quick-reference training guidebook with a flowchart outlining the data collection process will also be developed and provided to study site investigators as reference materials. Fig 3 depicts the data collection flowchart, as detailed in the training guidebook. Data collected will then be submitted to the research team for entry and analysis. Data collection flowchart. The study will include patients diagnosed with Type II diabetes mellitus who are Malaysian citizens aged 18 and above. Patients will be excluded if they have bilateral lower limb amputations, cognitive impairments, are dependent on caregivers for daily activities, or are not proficient in either Bahasa Malaysia or English. Patients may withdraw from the study at any time without penalty or consequence. They may continue their regular foot care follow-ups as usual. However, to maintain the required sample size, any withdrawn patients will be replaced. Ethical approval and study registration Participation in the study is entirely voluntary, and all recruited participants will provide written informed consent. They will be explicitly informed of the study’s nature, purpose, objectives, confidentiality and anonymity assurances, as well as their right to withdraw from the study at any time, should they wish to do so. No personal information will be disclosed when the findings of the study are published. The study will adhere to the ethical principles outlined in the Declaration of Helsinki and the Malaysian Good Clinical Practice Guidelines. It is registered with the National Medical Research Register (NMRR ID-24-00563-1ZX), and ethical approval has been granted by the Medical Research and Ethics Committee, Ministry of Health (ID-24-00563-1ZX). The study duration spans from August 2024 to April 2026. The pilot and field tests, during which patients will be recruited, are expected to begin in June 2025 and be completed by October/November 2025. The study is expected to be completed by April 2026. Data management and oversight Access to the data will be limited to the research team members directly involved in data analysis and processing. Strict confidentiality measures will be followed to protect the patients’ identities and sensitive information. All data will be anonymised, and unique identifiers will be assigned to patients to ensure confidentiality during analysis and reporting. The final refined version of the collected data will be stored in a designated repository in the Ministry of Health for seven years after the completion of the research. Statistical analysis plan All collected data will be subjected to regular quality checks, with the research team divided into small groups assigned to each study site to independently verify data entries. This process will ensure discrepancies are identified and resolved promptly, maintain completeness and accuracy in data entry. Statistical analyses will be performed using the Statistical Package for the Social Sciences (SPSS) Software (Version 26). Descriptive analysis will be used to describe the sociodemographic profiles. a) Content validity & face validity. The content validity will be estimated quantitatively using the CVI based on the expert panel evaluations (refer to Annex 4 in S1 File). A CVI of at least 0.83 will be considered acceptable [46]. Face validity will be estimated using FVI via a structured form (refer to Annex 4 in S1 File), wherein an FVI of at least 0.83 will be deemed acceptable [48]. Amendments will be made based on the feedback received. b) Reliability. Inter-item correlations between 0.15 and 0.5 will be deemed acceptable [56]. An item-total correlation of ≥ 0.3 will indicate that an item is related to the overall scale [57]. Cronbach’s α values of 0.7 or above will be considered acceptable [58]. Test-retest reliability will be determined using Intraclass Correlation Coefficient (ICC), with a value greater than 0.75 [59] demonstrating a good level of agreement. c) Exploratory factor analysis. The Kaiser-Meyer-Olkin (KMO) criterion will be assessed for sampling adequacy, with a value of ≥ 0.50 considered good [60]. A significant Chi-square value from Bartlett’s test of sphericity will indicate that relationships exist in the data, and at least one domain is present [57]. Domains will be extracted using principal axis factoring and according to the Kaiser criterion, domains with eigenvalues of ≥ 1.0 should be retained [61]. Following domain extraction, Promax rotation will be applied, and factor loadings of > 0.7 is desirable, with a minimum threshold of 0.4 [54]. d) Confirmatory factor analysis (CFA). When assessing the convergent validity, factor loadings and the average variance extracted (AVE) will be examined. Loading values ≥ 0.5 are acceptable, and high factor loading scores that contribute to AVE scores of greater than 0.5 will be deemed valid [62]. If convergent validity is not acceptable, items with low factor loadings will be reviewed and revised or removed as needed. Discriminant validity will be confirmed if the square root of each construct’s AVE exceeds its correlations with other latent constructs, as per the Fornell-Larcker criterion [63]. If discriminant validity is not acceptable, constructs showing significant overlap will be redefined, and items contributing to cross-loadings will be revised or excluded. Discussion This article outlines the methodology for the development and validation of a Malaysian diabetic foot self-care assessment instrument, addressing the current gap in locally suited instruments that are practical for daily use in our healthcare system. This article could serve as a guide for other Asian countries facing similar challenges, enabling them to develop their own instruments without concerns about proprietary restrictions. While several internationally available instruments exist for assessing diabetic foot self-care, developing a local instrument offers distinct advantages by catering to the unique needs of the Malaysian healthcare system and its population. This study’s short-term benefits lie in its ability to improve the diabetic foot care services provided to patients. International instruments may overlook local practices such as crossing legs and sitting on the floor, which commonly occurs during prayers, religious sermons, and certain cultural settings where meals are served while sitting on the floor. They may also miss practices such as washing of feet before prayers, while including less relevant practices such as the wearing of boots. A locally developed instrument tailored to Malaysia’s cultural and healthcare system capacity would make self-care assessments more understandable and resonate better with patients. By aligning with Malaysian lifestyles, this instrument allows healthcare providers to identify and address risk factors unique to Malaysia, such as foot care habits influenced by local cultural practices and traditional medicine. This approach will enable earlier interventions and more targeted support for high-risk patients. In the medium and long term, integrating this instrument into patient management can potentially reduce diabetic foot complications such as amputations and hospitalisations, through early identification and intervention. This reduction would alleviate the strain on healthcare resources, leading to a more efficient and sustainable healthcare system, while improving patients’ quality of life. Guided by the instrument, healthcare providers can tailor education plans specific to patients, addressing patient-specific issues, ensuring patient receives care that is relevant and effective, which aims to improve self-care practices, thereby improving outcomes. The instrument looks from the self-care perspective aiming to empower the community to take an active role in managing and preventing diabetes-related complications. This increased health literacy will foster a healthier and more informed population. The adoption of this locally developed instrument will also support the standardisation of diabetic foot care assessments across Malaysia and promote uniformity in clinical practice at the national level. This standardisation will facilitate benchmarking and continuous improvement, as healthcare providers can track progress and outcomes with greater precision. Beyond individual care, with nationwide uptake and consistent use of the instrument, a database of long-term trends in diabetic foot care can be generated. By providing policymakers with long-term, context-specific evidence, this approach can improve existing evidence-based guidelines and support research on innovative patient education and early intervention strategies tailored to the unique needs of Malaysian patients. It can also inform resource allocation for public health initiatives ensuring that patients receive care that is both relevant and effective. While this study has garnered support from relevant stakeholders, nevertheless, development of this instrument may still face several challenges. Firstly, ensuring the instrument is culturally sensitive and inclusive, reflecting Malaysia’s diverse population, though difficult, is crucial. Secondly, limited resources and time constraints may impact the study’s progress, while retaining a representative sample could prove challenging. Thirdly, the variability in healthcare infrastructure between urban and rural areas requires the instrument to be adaptable and effective across different settings. Finally, ensuring the instrument’s long-term sustainability and scalability is another challenge, ensuring it remains relevant and updated as practices and needs evolve. Conclusion Ultimately, while international instruments provide a general framework, a local instrument offers the distinct advantage of cultural relevance, better patient engagement, and the ability to address specific challenges faced by the Malaysian population. Developing a local instrument can contribute to significant improvements in patient care and long-term advancements in public health, self-empowerment, research, and healthcare policy. Supporting information All tables are provided in Annexes 1–4. (PDF) 5 May 2025 Dear Dr. Nair Narayanan, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== Please submit your revised manuscript by Jun 19 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Yee Gary Ang, MBBS MPH Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section. 3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. 4. We note that you have indicated that there are restrictions to data sharing for this study. For studies involving human research participant data or other sensitive data, we encourage authors to share de-identified or anonymized data. However, when data cannot be publicly shared for ethical reasons, we allow authors to make their data sets available upon request. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Before we proceed with your manuscript, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible. Please update your Data Availability statement in the submission form accordingly. 5. In the online submission form, you indicated that data used in this study is not publicly available due to confidentiality restrictions. However, data can be accessed upon reasonable request and subject to approval from the corresponding author or the Head of Centre for Biostatics & Data Repository, National Institutes of Health, Ministry of Health Malaysia on reasonable grounds for the request and with the permission from the Director General of Health, Malaysia. All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions 1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions? Reviewer #1: Yes ********** 2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses??> Reviewer #1: Partly ********** 3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable??> Reviewer #1: No ********** 4. Have the authors described where all data underlying the findings will be made available when the study is complete??> The PLOS Data policy Reviewer #1: No ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes ********** Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics. You may also provide optional suggestions and comments to authors that they might find helpful in planning their study. Reviewer #1: I see ethical problems with the use of items from other global scales and, worse, with the adaptation and modification of items from these scales without prior authorization from the authors of the original scales. I suggest taking the best scale and, with the authorization of the authors of the original scale, translating it into the language of your country. I recommend TO REFUSE to publish this article in its current form. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: Yes: THEREZA MARIA MAGALHÃES MOREIRA ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step. 19 May 2025 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf Response: Thank you for the guidance. Where applicable and required, the manuscript has been reformatted to align with the PLOS ONE style requirements. 2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section. Response: Thank you for highlighting the discrepancy. • I have amended the ‘Funding Information’ as instructed to ensure it is accurate to reflect the following: This research is funded by the Ministry of Health Malaysia Research Grant [Grant reference number: KKM.400-4/2/30 Jld.2 (52)]. The funding body is not involved in the study design, data collection and analysis, publication decision, or manuscript preparation. • Nevertheless, I am unable to amend the 'Financial Disclosure' section, as I no longer have access to it, possibly because the journal has not granted permission for further edits to that section. 3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. Response: Thank you for highlighting this important aspect. • We have now ensured that the full ethics statement is included exclusively in the “Methods” section (lines 377–389: marked up version), as advised. 4. We note that you have indicated that there are restrictions to data sharing for this study. For studies involving human research participant data or other sensitive data, we encourage authors to share de-identified or anonymized data. However, when data cannot be publicly shared for ethical reasons, we allow authors to make their data sets available upon request. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Before we proceed with your manuscript, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). b) Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. c) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. d) Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. e) You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible. Please update your Data Availability statement in the submission form accordingly. Response: Thank you for your detailed guidance on data sharing requirements. • As this is a study protocol, no data have been generated or analysed at this stage. However, we acknowledge the importance of data availability and have updated the “Data Availability Statement” section in the manuscript and submission form to reflect the following: • As this is a study protocol, no datasets have been generated or analysed at this stage. Upon completion and publication of the study, de-identified relevant research data will be made available upon reasonable request from the corresponding author or the Head of Centre for Biostatics & Data Repository, National Institutes of Health, Ministry of Health Malaysia, and subject to approval by the Director General of Health, Malaysia. (as elaborated from lines 370-376: marked up version) 5. Reviewer #1: I see ethical problems with the use of items from other global scales and, worse, with the adaptation and modification of items from these scales without prior authorization from the authors of the original scales. I suggest taking the best scale and, with the authorization of the authors of the original scale, translating it into the language of your country. I recommend TO REFUSE to publish this article in its current form. Response: Thank you for your valuable feedback. We understand and appreciate your concerns regarding the use and adaptation of existing global instruments. • In response, we have carefully reconsidered our approach and have revised the protocol accordingly. • The proposed study will no longer involve the adoption or adaptation of any existing scales; instead, we intend to develop a new Malaysian-specific instrument. • To inform/guide this development, the comprehensive literature review will examine the strengths and limitations of previously established instruments. • Insights gained from this review will guide the design of our instrument, aligning it with the specific needs of Malaysian stakeholders while also ensuring internationally recognised constructs to support cross-cultural comparability. • We are also mindful of potential proprietary and licensing issues that may arise from using established tools. For example, the Morisky Medication Adherence Scale, which was previously adopted and adapted in our country, later required licensing fees that became too costly for sustained national use and was eventually discontinued. • Developing a contextually relevant instrument from the outset will help us avoid such challenges and ensure broader accessibility for future nationwide implementation. • We remain committed to ethical research practices and will ensure that content drawn from existing instruments are appropriately acknowledged and cited. • Additionally, we have expanded the methodological section to provide greater detail on our instrument development process. This is intended to enhance transparency and support replicability of the study by researchers in other countries with similar contextual needs. • Amended in manuscript (marked up version) in the following lines: 28-31 92-95 97-99 120-125 147-151 158-165 174-178 256-257 312-315 321-322 326-328 391-392 421-423 6. Have the authors described where all data underlying the findings will be made available when the study is complete? Reviewer #1: No Response: Thank you for highlighting this important point. • As this is a study protocol, no datasets have been generated or analysed at this stage. • However, we have revised the manuscript under the “Data Availability Statement” clarifying that, upon completion and publication of the study, de-identified relevant data will be made available upon reasonable request from the corresponding author or the Head of the Centre for Biostatistics & Data Repository, National Institutes of Health, Ministry of Health Malaysia, and subject to approval by the permission from the Director General of Health, Malaysia. (as elaborated from lines 370-376: marked up version) 7. While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. Response: Thank you for the instructions. • All figure files have been uploaded to the Preflight Analysis and Conversion Engine (PACE) and have passed the required checks. • We have ensured that the figures meet PLOS formatting requirements. • Fig 1, Fig 2 and Fig 3 have been uploaded as .tif files, labelled accordingly (label of figure). Submitted filename: Response to Reviewers.docx 2 Jun 2025 Dear Dr. Nair Narayanan, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. We only managed to find one reviewer Please make the changes and consider resubmitting Please submit your revised manuscript by Jul 17 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Yee Gary Ang, MBBS MPH Academic Editor PLOS ONE Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions? Reviewer #2: Yes ********** 2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses??> Reviewer #2: Partly ********** 3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable??> Reviewer #2: Yes ********** 4. Have the authors described where all data underlying the findings will be made available when the study is complete??> The PLOS Data policy Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #2: Yes ********** Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics. You may also provide optional suggestions and comments to authors that they might find helpful in planning their study. Reviewer #2: The aim of this study protocol is describe the development and validation of a Malaysian diabetic foot self-care practice assessment instrument. In this revised version, the recommendations previously made have been taken into account and the manuscript has been improved, and I have only some minor comments. 1) At the end of the introduction, the aim and/or objectives of the study should be clearly defined. As the proposed study will first develop and then validate a national instrument, both aspects should also be mentioned in the objectives. As the authors have changed the structure of the study compared to the first version of the manuscript, they should also change the title. 2) Study type and design – please clearly state that the first stage is the development of the instrument and the second is the validation study. 3) Patients will be involved in the second phase of the study - validation through a cross-sectional study. However, the new instrument will be self-administered by the patients, so the patients should be involved already in the development process - from the definition of the topics/items of the instrument and the content validation, patients should be involved in the expert group, in addition it may be appropriate to conduct a qualitative survey among patients. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org 17 Jul 2025 Journal Requirements / Editor’s Comments: 1. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. Response: • Thank you for your attention to this detail. • I have carefully reviewed the entire manuscript to ensure that the ethics statement appears only in the Methods section. • The manuscript’s main sections are: Abstract, Introduction, Methods, Discussion, Conclusion, Acknowledgment, Supporting Information, and References. • Within the Methods section, the subheadings are: Study Type & Design, Phase 1: Development of the Malaysian Instrument, Phase 2: Validation of the Instrument, Study Population and Sampling, Statistical Analysis Plan, Data Management and Oversight, Data Availability Statement, and Ethical Approval & Study Registration. • I confirm that the ethics statement appears only under the Ethical Approval & Study Registration subheading within the Methods section and does not appear elsewhere in the manuscript. 2. • Please review your reference list to ensure that it is complete and correct. • If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. • Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. • If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Response: • We thank the reviewer for this important reminder. • In response, we undertook a thorough review of the entire reference list to ensure that every source cited is complete, verifiable, and fully compliant with PLOS ONE’s rigorous publication standards. • We confirm there were no retracted articles in the reference list. • Nevertheless, 3 references were removed as they may not meet the required standards for robust peer-review, retrievability, or scientific credibility: a. Goweda et al. (2017) was removed because it is not widely indexed and its content is sufficiently covered by stronger, peer-reviewed sources already included in the manuscript. b. AHS et al. (2018) was removed due to lack of indexing and unclear peer-review status. - To uphold the scientific foundation of this section, we actively replaced it with a more credible, peer-reviewed source (Sulistyo et al., 2018, Journal of Research in Nursing), which reports on the same instrument and context. c. Quadri et al. (2013) was removed as it is a conference abstract only, with no peer-reviewed full-text version available, and therefore does not meet PLOS ONE’s citation requirements. • By carefully verifying, removing, and replacing these references, we have taken deliberate steps to strengthen the scholarly rigor and integrity of the manuscript. • We have ensured that all references meet the journal’s expectations for transparency, retrievability, and quality. Reviewer’s Comments: 1. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses? The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory. Reviewer #2: Partly Response: • We have addressed these methodological aspects through our responses to the specific comments provided and have revised the manuscript accordingly to ensure sufficient detail, clarity, and transparency. 2. Review Comments to the Author: The aim of this study protocol is describe the development and validation of a Malaysian diabetic foot self-care practice assessment instrument. In this revised version, the recommendations previously made have been taken into account and the manuscript has been improved, and I have only some minor comments. Response: • We thank the reviewer for acknowledging the improvements and appreciate the constructive feedback provided throughout the review process. • We will address the remaining minor comments accordingly to further strengthen the manuscript. 3. Review Comments to the Author: • At the end of the introduction, the aim and/or objectives of the study should be clearly defined. • As the proposed study will first develop and then validate a national instrument, both aspects should also be mentioned in the objectives. Response: • We thank the reviewer for this valuable suggestion. • In response, we have revised the study objectives in both the Abstract and Introduction sections to explicitly state that the study involves both the development and validation of the national instrument. - Lines 23, 25, 26 (Abstract) - Line 130 (Introduction) • We believe this amendment clarifies the full scope of the study as intended. 4. Review Comments to the Author: As the authors have changed the structure of the study compared to the first version of the manuscript, they should also change the title. Response: • We thank the reviewer for this constructive suggestion. We concur that the revised structure of the study should be clearly reflected in the title. • Accordingly, we have amended the title to: “Stepping Forward: A Study Protocol for Developing and Validating a Malaysian Diabetic Foot Self-care Practice Assessment Instrument” and the short title to “Developing and validating a Malaysian diabetic foot self-care practice assessment instrument” • These revised titles more accurately represent the comprehensive scope of the study, which now encompasses both the development and validation phases of the proposed national instrument. 5. Review Comments to the Author: Study type and design - please clearly state that the first stage is the development of the instrument and the second is the validation study. Response: • We thank the reviewer for this helpful suggestion. • We have revised the manuscript to clearly state that Phase 1 involves the development of the instrument and Phase 2 involves its validation through a cross-sectional study design. - Lines 144-146 - Lines 383-386 6. Review Comments to the Author: • Patients will be involved in the second phase of the study - validation through a cross-sectional study. • However, the new instrument will be self-administered by the patients, so the patients should be involved already in the development process - from the definition of the topics/items of the instrument and the content validation, patients should be involved in the expert group, in addition it may be appropriate to conduct a qualitative survey among patients. Response: • We sincerely thank the reviewer for highlighting this important point. • We agree that incorporating patient perspectives is crucial to ensure that the instrument is clear, relevant, and practical for its intended users. • In Phase 1, the domains and items will be systematically drafted based on established national diabetic foot care guidelines and robust international evidence. • This initial version will undergo expert content validation by a panel of healthcare professionals with extensive experience in diabetic foot care to ensure clinical relevance and accuracy. • To ensure that the instrument also meets patient needs and expectations, patients will be involved in the face validity process in Phase 1 through pre-testing and cognitive debriefing. • This will include: - A short, structured feedback form for patients - Cognitive debriefing interviews to gather in-depth feedback on wording, cultural appropriateness, and ease of use • We will carefully analyse this feedback to refine the instrument before proceeding to piloting and field-testing in Phase 2 : Lines 216–232 • This multi-step approach ensures that the instrument content is evidence-based, clinically sound, and meaningfully co-shaped by patient input, hence maximizing its practical usability and cultural appropriateness. Submitted filename: Response to Reviewers (Cycle 2).docx 14 Nov 2025 Stepping forward: A study protocol for developing and validating a Malaysian diabetic foot self-care practice assessment instrument PONE-D-25-16530R2 Dear Dr. Nair Narayanan, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support . If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Yee Gary Ang, MBBS MPH Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions? Reviewer #2: Yes Reviewer #3: Yes ********** 2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses??> Reviewer #2: Yes Reviewer #3: Yes ********** 3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable??> Reviewer #2: Yes Reviewer #3: Yes ********** 4. Have the authors described where all data underlying the findings will be made available when the study is complete??> The PLOS Data policy Reviewer #2: Yes Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #2: Yes Reviewer #3: Yes ********** Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics. You may also provide optional suggestions and comments to authors that they might find helpful in planning their study. Reviewer #2: In this revised version, the recommendations previously made have been taken into account and the manuscript has been improved, and I have no further suggestions. Reviewer #3: The revision is clear and practical, and the steps are easy to follow for replication. The study idea fits well with current work in this area. I don’t see major problems. I think this protocol can be accepted for publication. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #2: Yes: Kaja Põlluste Reviewer #3: No ********** PONE-D-25-16530R2 PLOS One Dear Dr. Nair Narayanan, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Yee Gary Ang Academic Editor PLOS One